P
PROTAGONIST THERAPEUTICS INC
NASDAQ: PTGX (Protagonist Therapeutics, Inc.)
Kemas kini terakhir: 2 jam lalu99.36
0.51 (0.52%)
| Penutupan Terdahulu | 98.85 |
| Buka | 98.51 |
| Jumlah Dagangan | 505,003 |
| Purata Dagangan (3B) | 745,040 |
| Modal Pasaran | 6,389,978,112 |
| Harga / Pendapatan (P/E Ke hadapan) | 23.81 |
| Harga / Jualan (P/S) | 137.49 |
| Harga / Buku (P/B) | 10.41 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2026 |
| Margin Keuntungan | 27.04% |
| Margin Operasi (TTM) | -68.18% |
| EPS Cair (TTM) | 0.780 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -88.90% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 381.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.65% |
| Nisbah Semasa (MRQ) | 17.25 |
| Aliran Tunai Operasi (OCF TTM) | 336.94 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 327.76 M |
| Pulangan Atas Aset (ROA TTM) | 2.48% |
| Pulangan Atas Ekuiti (ROE TTM) | 8.99% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Protagonist Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
1.0
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.00 |
|
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.10% |
| % Dimiliki oleh Institusi | 108.49% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Farallon Capital Management Llc | 31 Dec 2025 | 6,144,006 |
| Rtw Investments, Lp | 31 Dec 2025 | 5,059,053 |
| Janus Henderson Group Plc | 31 Dec 2025 | 2,649,981 |
| Johnson & Johnson | 31 Dec 2025 | 2,449,183 |
| Woodline Partners Lp | 31 Dec 2025 | 1,408,772 |
| Perceptive Advisors Llc | 31 Dec 2025 | 1,350,425 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 113.00 (Barclays, 13.73%) | Beli |
| Median | 106.00 (6.68%) | |
| Rendah | 95.00 (Goldman Sachs, -4.39%) | Pegang |
| Purata | 105.00 (5.68%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 89.12 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 03 Mar 2026 | 95.00 (-4.39%) | Pegang | 91.30 |
| Barclays | 26 Feb 2026 | 113.00 (13.73%) | Beli | 88.39 |
| Citizens | 26 Feb 2026 | 112.00 (12.72%) | Beli | 88.39 |
| TD Cowen | 26 Feb 2026 | 100.00 (0.64%) | Beli | 88.39 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Mar 2026 | CNBC | FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |